Clinical Trial Update: Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating LY2062430 in subjects with mild-to-moderate Alzheimer's disease and in healthy volunteers has completed; results were reported from thi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LY2062430

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED